新疆天山畜牧生物工程股份有限公司 2024 年度独立董事述职报告 一、独立董事的基本情况 本人张佑民，1962 年 11 月出生，中国国籍，无境外永久居留权，中共党员， 专科学历，注册会计师（非执业）、注册税务师、资产评估师、房地产估价师、 土地估价师。曾任湖南英特会计师事务所高级经理；湖南中兴会计师事务所高级 经理；湖南开元会计师事务所高级经理。现任北京坤元至诚资产评估有限公司（原 名：开元资产评估有限公司）首席评估师、总公司党支部书记、董事；公司第五 届董事会独立董事、审计委员会主任委员、提名委员会委员、战略委员会委员。 新疆天山畜牧生物工程股份有限公司 2024 年度独立董事述职报告 ——独立董事 张佑民 本人作为新疆天山畜牧生物工程股份有限公司（以下简称"公司"）的独立 董事，在2024年任职期间工作中严格按照《公司法》《证券法》《公司章程》《上 市公司独立董事管理办法》等有关法律法规、证券交易所业务规则和《公司章程》 《公司董事会议事规则》《公司独立董事工作制度》等制度的规定和要求，勤勉 尽责，认真审议董事会各项议案，充分发挥独立董事的独立作用，切实维护了公 司整体利益和保护全体股东特别是中小股东的 ...

新疆天山畜牧生物工程股份有限公司 2024 年度独立董事述职报告 新疆天山畜牧生物工程股份有限公司 2024 年度独立董事述职报告 ——独立董事 吴新忠 本人作为新疆天山畜牧生物工程股份有限公司（以下简称"公司"）的独立 董事，在2024年任职期间工作中严格按照《公司法》《证券法》《公司章程》《上 市公司独立董事管理办法》等有关法律法规、证券交易所业务规则和《公司章程》 《公司董事会议事规则》《公司独立董事工作制度》等制度的规定和要求，勤勉 尽责，认真审议董事会各项议案，充分发挥独立董事的独立作用，切实维护了公 司整体利益和保护全体股东特别是中小股东的合法权益。现将2024年度任职期间 履行独立董事职责情况向各位述职如下： 二、独立董事年度履职概况 （一）出席股东大会、董事会会议情况 本人秉承勤勉尽责的态度，积极参加公司召开的董事会。2024 年任职期间， 公司共召开 8 次董事会和 2 次股东大会。本人出席 8 次董事会，列席 2 次股东大 会，无缺席或连续两次未亲自参加会议的情况，本人也未有提议召开董事会的情 形。 对于董事会所议事项，本人在各次会议召开前主动调查和获取作出决策所需 要的相关资料，与管理层 ...

——独立董事 高超 本人作为新疆天山畜牧生物工程股份有限公司（以下简称"公司"）的独立 董事，在2024年任职期间工作中严格按照《公司法》《证券法》《公司章程》《上 市公司独立董事管理办法》等有关法律法规、证券交易所业务规则和《公司章程》 《公司董事会议事规则》《公司独立董事工作制度》等制度的规定和要求，勤勉 尽责，认真审议董事会各项议案，充分发挥独立董事的独立作用，切实维护了公 司整体利益和保护全体股东特别是中小股东的合法权益。现将2024年度任职期间 履行独立董事职责情况向各位述职如下： 一、独立董事的基本情况 新疆天山畜牧生物工程股份有限公司 2024 年度独立董事述职报告 新疆天山畜牧生物工程股份有限公司 2024 年度独立董事述职报告 本人高超，1966 年 3 月出生，中国国籍，无境外永久居留权，中共党员， 本科学历，律师。曾任昌吉学院法学副教授；新疆东方环宇燃气股份有限公司独 立董事；西域旅游开发股份有限公司独立董事；公司第二届、第三届独立董事。 现任新疆同创律师事务所律师；乌鲁木齐仲裁委员会仲裁员；乌鲁木齐仲裁委员 会昌吉分会仲裁员；公司第五届董事会独立董事、提名委员会主任委员、薪酬与 考核委 ...

二〇二五年四月二十九日 1 新疆天山畜牧生物工程股份有限公司 董事会关于独立董事 2024 年度独立性情况的专项意见 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）董事会根据《公 司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票 上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》《公司章程》《公司独立董事工作制度》等法律法规的有关规定,并 结合独立董事提交的独立性自查报告，就公司在任独立董事独立性情况进行评估 并出具如下专项意见： 经核查，董事会认为：公司独立董事张佑民先生、吴新忠先生、高超女士具 备胜任独立董事岗位的资格，其本人及其配偶、父母、子女、主要社会关系未在 公司或公司附属企业任职，未在公司主要股东及其附属企业任职，与公司不存在 重大利害关系或其他可能妨碍其进行独立客观判断的关系，不存在影响任职独立 性的情况，符合《上市公司独立董事管理办法》《公司章程》及《公司独立董事 工作制度》等法律法规中关于独立董事任职资格及独立性的要求。 新疆天山畜牧生物工程股份有限公司董事会 ...

Financial Performance - The company reported a significant decline in live cattle market prices, leading to increased losses in its livestock business[3]. - The sales volume of the high-margin frozen semen business decreased, resulting in reduced profitability[3]. - The newly launched meat slaughtering and processing business has not yet achieved profitability as it is still in its initial phase[3]. - The company has recognized asset impairment provisions for inventories, fixed assets, and investment properties due to estimated recoverable amounts being lower than their book values[3]. - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves[4]. - The audit report issued by Zhongxing Caiguanghua Certified Public Accountants includes a section on significant uncertainties related to going concern[3]. - The company’s operating revenue for 2024 was ¥137,601,816.77, a slight increase of 0.07% compared to ¥137,499,875.86 in 2023[20]. - The net profit attributable to shareholders for 2024 was negative at -¥65,947,904.35, representing a significant decline of 199.74% from -¥22,001,636.31 in 2023[20]. - The net cash flow from operating activities for 2024 was ¥14,357,578.16, a substantial improvement of 204.44% compared to -¥13,747,711.18 in 2023[20]. - The company's total assets at the end of 2024 were ¥248,197,118.59, a decrease of 21.26% from ¥315,229,860.70 at the end of 2023[20]. - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of -¥67,545,934.55 for 2024, down 172.25% from -¥24,810,107.89 in 2023[20]. - The company experienced a negative net profit for the last three accounting years, indicating ongoing uncertainty regarding its ability to continue as a going concern[20]. - The company reported a total of ¥1,598,030.20 in non-recurring gains for 2024, compared to ¥2,808,471.58 in 2023[26]. - The company reported an operating loss of 61.34 million yuan, a year-on-year increase in loss of 228.69%[66]. - The total assets of the company decreased by 21.26% compared to the beginning of the year, amounting to 248.20 million yuan[66]. - The company’s equity attributable to shareholders decreased by 106.08%, amounting to -3.78 million yuan[66]. Market Conditions - The average monthly price of beef (boneless) and live cattle was 69.83 CNY/kg and 27.76 CNY/kg respectively, representing a decline of 15% and 20% year-on-year, marking the lowest prices in five and ten years respectively[38]. - The beef cattle industry in China has seen a stable growth in production capacity, with the total cattle inventory reaching 100.47 million heads in 2024, an increase of approximately 11.81% compared to 2013[37]. - The beef cattle industry is experiencing cyclical fluctuations, with many large-scale farming enterprises facing significant losses due to declining market prices[39]. - The entire beef cattle industry chain is facing losses at the farming level, while downstream sectors such as live cattle circulation and beef sales remain relatively stable in profitability[40]. - The average price of fattened cattle in China dropped from 35.1 RMB/kg in 2022 to 30.02 RMB/kg in 2023, with a further decline to approximately 25.39 RMB/kg in June 2023, marking the lowest price since November 2017[114]. - The beef cattle market is expected to continue its downward trend, with prices in mid-April 2024 dropping to levels not seen since 2012, affecting the company's farming operations[115]. Business Strategy and Operations - The company operates primarily in the livestock industry, with approximately 80% of its business focused on cattle breeding and beef cattle farming[28]. - The company is positioned in a growing industry with significant market potential, particularly in the beef cattle sector, which is still in its early stages of development in China[28]. - The company is expanding its business model to include downstream slaughter processing and meat sales in Guangdong, aiming for a full industry chain layout from breeding to table[43]. - The company has established a modern breeding system integrating breeding, nutrition, and disease prevention, providing comprehensive services to cattle farmers[42]. - The company is actively involved in the establishment of the "Beef Simmental Breeding Alliance" to enhance innovation capabilities in the beef industry[42]. - The company aims to focus on the Chinese beef cattle industry, implementing a "big beef cattle strategy" to drive breeding and beef cattle farming[105]. - The company plans to expand its downstream operations in live cattle circulation, slaughter processing, and meat sales[105]. - The company will continue to develop its breeding and beef cattle farming businesses while expanding into live cattle circulation, slaughter processing, and meat sales to enhance the entire industry chain[110]. Legal and Compliance Issues - The company is currently facing litigation risks due to investor claims related to the restructuring of the Elephant Advertising incident, with ongoing legal efforts to minimize losses[118]. - The company has been involved in contract fraud cases, with final judgments affecting agreements made in September 2017, and is actively pursuing the recovery of related shares[119]. - The company is involved in ongoing litigation regarding advertising rights but has not incurred any losses as of the date of the commitment[176]. - The company has committed to bear all economic compensation responsibilities related to the legal case if the transaction is approved and results in a final judgment against it[178]. - The audit report for the 2023 fiscal year from Zhongxing Cai Guanghua CPA included a section on significant uncertainties related to going concern, but the board respects the audit opinion and aims to address the highlighted issues[188]. Governance and Management - The company held two shareholder meetings during the reporting period, adhering to all relevant regulations and ensuring equal treatment of all shareholders[126]. - The board of directors consists of nine members, with independent directors making up at least one-third of the board, ensuring compliance with governance standards[128]. - The supervisory board is composed of three members, including a representative from employees, fulfilling legal requirements for oversight[129]. - The company maintains strict compliance with information disclosure regulations, ensuring timely and accurate communication with investors[131]. - The company's governance practices align with regulatory requirements, with no significant discrepancies noted[131]. - The company has established a remuneration and assessment committee to determine the remuneration plans for directors and senior management[144]. - The company has a total of 10 board members, including independent directors and supervisors[143]. - The company has a complete production, sales, and R&D system, enabling independent market operations[132]. Employee and Training Initiatives - The total number of employees at the end of the reporting period is 124, with 19 in the parent company and 105 in major subsidiaries[153]. - Employee training programs are implemented, combining internal and external training to enhance skills and management capabilities[155]. - The professional composition includes 42 production personnel, 15 sales personnel, 16 technical personnel, 16 financial personnel, 18 administrative personnel, 11 management personnel, and 6 logistics personnel[153]. Risk Management - The company is facing significant risks, including potential delisting due to negative net profits for three consecutive years and a negative net asset value as of the end of 2024[113]. - The company faces significant risks from animal diseases, which can severely impact production and reproduction capabilities, potentially leading to substantial losses[117]. - The company has implemented various disease prevention measures, including isolation, disinfection, and vaccination, to mitigate the risk of outbreaks[117]. - The company acknowledges the impact of the audit report indicating significant uncertainties regarding its going concern and is committed to taking effective measures to mitigate these issues[194]. Investment and Financial Management - The company plans to optimize its asset structure by disposing of long-term idle assets to reduce financial burdens and enhance its competitive edge[112]. - The company aims to strengthen its financial management to gradually improve its asset-liability structure and enhance its risk resistance capabilities[190]. - The company intends to build a professional team by attracting experienced industry talent and establishing a scientific incentive mechanism to boost team motivation[191]. - The company will explore capital operations to improve its capital structure and support long-term development[192].

Financial Performance - The company's operating revenue for Q1 2025 was ¥24,648,491.40, representing a 40.50% increase compared to ¥17,543,154.91 in the same period last year[5] - The net profit attributable to shareholders was -¥4,959,240.35, an improvement of 31.19% from -¥7,206,692.62 year-on-year[5] - The company reported a net loss of CNY 493,247,696.76 in retained earnings, worsening from a loss of CNY 488,288,456.41[31] - Net profit for the current period was -¥4,778,549.77, an improvement from -¥6,826,573.04 in the previous year, indicating a reduction in losses[33] - The company’s total profit (loss) for the current period was -¥3,862,240.81, an improvement from -¥5,708,458.86 in the previous year[33] - Basic and diluted earnings per share were both -0.0158, an improvement from -0.0230 in the same period last year[33] Cash Flow and Assets - The net cash flow from operating activities was -¥7,145,943.07, a significant decline of 231.73% compared to ¥5,424,757.22 in the previous year[5] - The cash inflow from operating activities decreased by 35.96% to ¥19,728,818.07 from ¥30,809,346.05 year-on-year[12] - The company's cash and cash equivalents decreased from CNY 24,500,019.79 to CNY 17,622,166.54, representing a decline of approximately 28.0%[29] - Cash and cash equivalents at the end of the period totaled ¥17,546,543.73, down from ¥22,446,910.25 at the end of the previous year[36] - The company's current assets decreased from CNY 62,540,010.51 to CNY 57,652,679.04, reflecting a decline of approximately 7.4%[29] - The total assets at the end of the reporting period were ¥239,741,075.73, down 3.41% from ¥248,197,118.59 at the end of the previous year[5] Operating Costs and Expenses - The company reported a 27.85% increase in operating costs, totaling ¥21,832,310.58, compared to ¥17,076,295.46 in the same period last year[11] - Total operating costs increased to ¥30,449,510.22, up 23.1% from ¥24,744,512.43 year-on-year[32] - Research and development expenses were ¥209,464.91, slightly down from ¥212,759.43 year-on-year[33] - The company reported a decrease in sales expenses to ¥571,658.47 from ¥646,415.23 year-on-year, reflecting cost control measures[33] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,020[13] - The controlling shareholder, Huzhou Haohui, holds 69,211,312 shares, accounting for 22.11% of the total shares[17] - Huzhou Haohui has pledged a total of 15,350,000 shares, which is 22.18% of its holdings and 4.90% of the total shares[20] - Chen Dehong holds 34,279,083 shares, representing 10.95% of the total shares, with 33,509,768 shares pledged, equating to 97.76% of his holdings[21] Legal and Regulatory Issues - The company is involved in a legal case regarding the execution of pledged shares, with 13,509,768 shares under dispute[22] - The company has been pursuing the recovery of shares from a fraud case involving its former actual controller, Chen Dehong, with 37,279,083 shares to be returned[19] - The company has received a final judgment in a civil lawsuit related to the fraud case, which may impact its financial position[19] - The company is currently facing uncertainty regarding the bankruptcy proceedings of its controlling shareholder, which may affect its operations[16] Strategic Developments - The company established a joint venture, Guangdong Tiansheng Agricultural Technology Co., Ltd., to enhance its operational strategy and profitability[26] - The company plans to reduce its planting area due to government water resource management policies, with the area decreasing to 21,532 acres by 2025[25] - The company is in the process of liquidating its subsidiary, Ningxia Meijia Agricultural Biotechnology Development Co., Ltd., due to poor performance and strategic misalignment[27] - The company has recognized an impairment provision of CNY 28.69 million for agricultural development land due to potential impairment signs[25] Other Income - The company recorded a 758.60% increase in other income, amounting to ¥2,126,416.62, compared to ¥247,660.27 in the previous year[11] - Other income increased significantly to ¥2,126,416.62 from ¥247,660.27 in the previous year, showing a substantial growth[33]

1、经财务部门测算，预计公司 2024 年度归属于上市公司股东的净利润为- 7,500万元至-6,300万元，扣除非经常性损益后的净利润为-7,600万元至-6,400 万元，扣除后营业收入为 8,500 万元至 9,900 万元，期末归母净资产为-1,200 万元至-100 万元。根据《深圳证券交易所创业板股票上市规则》第 10.3.1 条规 定，在公司 2024 年年度报告披露后，如公司 2024 年度经审计的净利润为负值 且营业收入低于 1 亿元，或 2024 年度经审计的期末净资产为负值，公司股票将 可能在 2024 年年度报告披露后被实施退市风险警示（股票简称前冠以"*ST"字 样）。 证券代码：300313 证券简称：ST天山 公告编号：2025-013 新疆天山畜牧生物工程股份有限公司 关于公司股票交易可能被实施退市风险警示的 第三次风险提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 风险提示： 2、公司股票自 2021 年 4 月 28 日开市起已被实施其他风险警示。截至本报 告披露日，其他风险警示事项仍然存在，公司股票将继续被实施 ...

证券代码：300313 证券简称：ST天山 公告编号：2025-014 新疆天山畜牧生物工程股份有限公司 关于董事辞职的公告 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）董事会近日收到 公司董事王胜利先生的书面辞职报告。王胜利先生因到龄退休原因辞去公司董事 及战略委员会委员职务，辞职后不再担任公司任何职务。 王胜利先生的原定任期至第五届董事会届满。根据《公司法》及《公司章程》 等相关规定，王胜利先生的辞职不会导致公司董事会成员低于法定最低人数，也 不会影响公司相关工作的正常进行，辞职报告自送达公司董事会之日起生效。截 至本公告日，王胜利先生未持有公司股票，不存在违反相关承诺的情形。 公司董事会对王胜利先生在任职期间为公司经营发展做出的贡献表示衷心 的感谢！ 特此公告。 新疆天山畜牧生物工程股份有限公司董事会 二〇二五年四月十一日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 ...

证券代码：300313 证券简称：ST天山 公告编号：2025-012 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）2025 年 3 月销 售活畜 6 头，销售收入 8.92 万元，环比变动分别为 100%、100%；同比变动分别 为-99.10%、-98.92%。 二、原因说明 鉴于公司现阶段面临较大的资金压力，为确保公司整体运营稳定，公司决定 对上游养殖业务实施战略性收缩调整。后续待公司资金状况改善并具备发展条件 时，公司将依据市场环境及公司实际情况，适时、适度地扩大养殖规模，推动业 务的持续发展。 三、风险提示 （一）上述数据未经审计，可能与公司定期报告披露的数据存在差异，因此 上述数据仅作为阶段性数据供投资者参考。 新疆天山畜牧生物工程股份有限公司 2025 年 3 月活畜销售情况简报 （二）上述披露仅包含公司活畜销售情况，不含其它业务。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、2025 年 3 月销售情况简报 二〇二五年四月十一日 （三）《证券时报》《上海证券报》以及巨潮资讯网（www.cninfo.com.cn） 为公司指定的信 ...

证券代码：300313 证券简称：ST天山 公告编号：2025-010 新疆天山畜牧生物工程股份有限公司 2025 年 2 月活畜销售情况简报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、2025 年 2 月销售情况简报 （二）上述披露仅包含公司活畜销售情况，不含其它业务。 （三）《证券时报》《上海证券报》以及巨潮资讯网（www.cninfo.com.cn） 为公司指定的信息披露媒体，公司所有信息均以公司在上述媒体刊登的公告为准。 敬请广大投资者审慎决策，注意投资风险。 特此公告。 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）2025 年 2 月销 售活畜0头，销售收入0元，环比变动分别为-100%、-100%；同比变动分别为-100%、 -100%。 二、原因说明 本月活畜销售数量、销售收入变动的主要原因是：基于活牛整体市场行情及 全产业链布局考量，公司将资源聚焦于屠宰加工及肉制品销售等下游环节；同时 受制于资金影响，公司缩减上游养殖业务规模，优化资产配置。 三、风险提示 （一）上述数据未经审计，可能与公司定期报告披露的数据存在差异，因此 上 ...